Namenda

Amantadine derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. ..

Medicinal name:
  • Pack [Namenda 28 Titration Pack]
  • Memantine hydrochloride 10 MG Oral Tablet [Namenda]
  • Namenda 5 MG Oral Tablet
  • Memantine hydrochloride 5 MG Oral Tablet [Namenda]
  • Namenda 10 MG Oral Tablet
  • Pack [Namenda 49 Titration Pack]
  • 24 HR Memantine hydrochloride 21 MG Extended Release Oral Capsule [Namenda]
  • 24 HR Memantine hydrochloride 28 MG Extended Release Oral Capsule [Namenda]
  • 24 HR Memantine hydrochloride 7 MG Extended Release Oral Capsule [Namenda]
  • 24 HR Memantine hydrochloride 14 MG Extended Release Oral Capsule [Namenda]

Namenda - Pharmacology:

Namenda exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg2+ ions and allow continuous influx of Ca2+ ions into cells and ultimately neuronal degeneration. Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate.

Namenda mini report

Namenda NDA
NDA - A product marketed under an approved New Drug Application
Namenda CAPSULE, EXTENDED RELEASE
CAPSULE, EXTENDED RELEASE
Namenda KIT
KIT
Namenda SOLUTION
SOLUTION
Namenda TABLET
TABLET
Namenda HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Namenda global name
memantine hydrochloride
Namenda global name
Memantine Hydrochloride
Start - Stop data
START DATA:
2011-Oct-31
Start - Stop data
STOP DATA
not occurred

Namenda for patients

Information for Patients and Caregivers: Caregivers should be instructed in the recommended administration (twice per day for doses above 5 mg) and dose escalation (minimum interval of one week between dose increases).

Namenda Interactions

N-methyl-D-aspartate (NMDA) antagonists: The combined use of NAMENDA with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.

Effects of NAMENDA on substrates of microsomal enzymes: In vitro studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. In addition, in vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, CYP2C9, CYP2E1 and CYP3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected.

Effects of inhibitors and/or substrates of microsomal enzymes on NAMENDA: Namenda is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine.

Acetylcholinesterase (AChE) inhibitors: Coadministration of NAMENDA with the AChE inhibitor donepezil HCl did not affect the pharmacokinetics of either compound. In a 24-week controlled clinical study in patients with moderate to severe Alzheimerís disease, the adverse event profile observed with a combination of memantine and donepezil was similar to that of donepezil alone.

Drugs eliminated via renal mechanisms: Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, coadministration of NAMENDA and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%. In addition, coadministration of memantine with the antihyperglycemic drug GlucovanceÒ (glyburide and metformin HCl) did not affect the pharmacokinetics of memantine, metformin and glyburide. Furthermore, memantine did not modify the serum glucose lowering effect of GlucovanceÒ.

Drugs that make the urine alkaline: The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.

Namenda Contraindications

NAMENDA (memantine hydrochloride) is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation.

Manufacturers name:

  • Forest Laboratories, Inc
  • Cardinal Health
  • Contract Pharmacy Services-PA
  • Physicians Total Care, Inc
  • Bryant Ranch Prepack
  • PD-Rx Pharmaceuticals, Inc
  • Rebel Distributors Corp
  • Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC

Generic name, Overdose, Half Life Namenda, Food Interactions, Chemical, etc..

Namenda see also Saw Palmetto

Brand Names containing Memantine

Chemical structure:
H N H H H H H H H H H H H H H H H H H H H H C12H21N 2D chemical structure C12H21N SVG | 2D structure Rimantadine | Memantine | chemical names, chemical properties, classification C12H21N